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Background: The role of the immune system in the pathophysiology of acute ischemic stroke is increasingly
recognized. However, targeted treatment strategies to modulate immunological pathways in stroke are still lacking.
Glatiramer acetate is a multifaceted immunomodulator approved for the treatment of relapsing-remitting multiple
sclerosis. Experimental studies suggest that glatiramer acetate might also work in other neuroinflammatory or
neurodegenerative diseases apart from multiple sclerosis.
Findings: We evaluated the efficacy of glatiramer acetate in a mouse model of brain ischemia/reperfusion injury.
60 min of transient middle cerebral artery occlusion was induced in male C57Bl/6 mice. Pretreatment with
glatiramer acetate (3.5 mg/kg bodyweight) 30 min before the induction of stroke did not reduce lesion volumes or
improve functional outcome on day 1.
Conclusions: Glatiramer acetate failed to protect from acute ischemic stroke in our hands. Further studies are
needed to assess the true therapeutic potential of glatiramer acetate and related immunomodulators in brain
ischemia.
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For many years ischemic stroke has been regarded as a
mere thrombo-embolic disease. However, there is increa-
sing evidence that the immune system is also critically
involved in stroke occurrence and development [1,2].
Brain ischemia triggers rapid activation of cerebral endo-
thelial cells and the release of danger signals from dying
neuronal tissues. As a consequence, different cell adhesion
receptors are upregulated and soluble chemoattractants
such as chemokines and cytokines are secreted that guide
the targeted invasion of innate immune cells (neutrophils,
macrophages) to the sites of tissue damage [2]. These per-
ipheral immune cells in concert with resident cell popula-
tions like microglia or astrocytes produce a potpourri of
potentially harmful mediators (e.g. reactive oxygen spe-
cies, degrading enzymes) and this sterile inflammation
further perpetuates the ischemic cascade. Interestingly,
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mice lacking functional T lymphocytes develop dramatic-
ally smaller brain infarctions and less severe functional
deficits after transient middle cerebral artery occlusion
[3-5]. Of note, distinct T cell subsets for instance regula-
tory T cells (Treg) or γδ T cells exist that are particularly
harmful in stroke [5]. Given that the immune system is of
significant relevance for the pathophysiology of acute is-
chemic stroke, it seems reasonable to evaluate the safety
and efficacy of specific immunomodulatory compounds in
terms of stroke prevention and treatment.
Glatiramer acetate (GA) is a synthetic peptide that con-
sists of four amino acids in a fixed molar residue ratio [6].
The substance for many years is in clinical use for the
treatment of relapsing-remitting multiple sclerosis and
has demonstrated to suppress experimental allergic en-
cephalomyelitis (EAE), the most common animal model
of multiple sclerosis [6]. The exact mode of action of GA
in autoimmune neuroinflammation is still unclear but
among other things is based on its ability to inhibit Th1
proinflammatory cytokines and to induce Th2 cell and
Treg activation or to reduce monocyte reactivity [7].
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a role [8]. However, the therapeutic potential of GA in
ischemic stroke is unclear and previous studies in rodents
produced controversial results [9,10]. Here, we investi-
gated the effect of GA on stroke outcome in a well-
established mouse model of brain ischemia/reperfusion
injury.
All experiments were approved by the respective insti-
tutional (University of Würzburg, Germany; University
of Münster, Germany) and governmental authorities
(Regierung von Unterfranken and Landesamt für Natur,
Umwelt und Verbraucherschutz Nordrhein-Westfalen).
Six to eight week old male C57Bl/6 mice weighing
20–25 g were used in the study which was conducted in
accordance with the recently published ARRIVE guide-
lines (http://www.nc3rs.org/ARRIVE). 60 min of transient
middle cerebral artery occlusion (tMCAO) using a mono-
filament was performed as described [11]. This model
mounts a strong and immediate local inflammatory re-
sponse in the ischemic brain [12]. GA (TEVA Pharma,
3.5 mg/kg bodyweight) [13] or vehicle (NaCl 0.9%) were
injected intravenously 30 min before tMCAO. Animals
were randomly assigned to the operators by an indepen-
dent person not involved in data acquisition and analysis.Figure 1 Glatiramer acetate (GA) does not protect from acute brain is
5-triphenyltetrazolium chloride stains of 3 corresponding coronal brain sectio
1 after transient middle cerebral artery occlusion (tMCAO). GA was applied 30
appeared to be similar between the two groups and this was confirmed by in
functional outcome on day 1 after tMCAO. The Bederosn score (left panel) an
and vehicle-treated controls (n = 5-7/group). Unpaired, 2-tailed Student’s t tes
n.s. = not significant.We performed surgery and evaluation of all read-out pa-
rameters while being blinded to the experimental groups.
Infarct volumes were calculated from coronal brain slices
stained with 2,3,5-triphenyltetrazolium chloride (TTC)
24 h after tMCAO [11]. The Bederson score [14] and the
grip test score [15] were assessed to monitor global neuro-
logic function, motor function, and coordination.
Stroke volumes were expressed as mean ± SEM. Func-
tional outcome parameters were depicted as scatter plots
including median with the 25% percentile and the 75%
percentile given in brackets in the text. For statistical ana-
lysis, the GraphPad Prism 5.0 software package (GraphPad
Software) was used. Data were tested for Gaussian dis-
tribution with the D’Agostino and Pearson omnibus
normality test and then analyzed by unpaired, two-tailed
Student´s t-test or Mann Whitney U test. P values < 0.05
were considered statistically significant.
Prophylactic administration of GA did not alter stroke
outcome (Figure 1). Stroke volumes on day 1 after 60 min
tMCAO were similar between GA-treated mice and vehicle-
treated controls (66.4 mm3± 37.3 mm3 vs. 76.7 mm3 ±
31.0 mm3, n = 7, p > 0.05) (Figure 1A). Accordingly,
no differences in functional outcome parameters were
observed (Bederson score: 3.0 [2.0, 3.0] vs 3.0 [1.0, 3.0],chemia/reperfusion injury. (A) (Left panel) Representative 2,3,
ns of a GA-treated mouse and a vehicle-treated mouse sacrificed on day
min before tMCAO at a dosage of 3.5 mg/kg bodyweight. Stroke sizes
farct volumetry (right panel) (n = 7/group). (B) GA did not improve
d the grip test (right panel) did not differ between GA-treated mice
t (infarct volumes) or Mann–Whitney Test (Bederson score, grip test);
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n = 5–7, p > 0.05) (Figure 1B).
The present study failed to demonstrate a protective
effect of GA in experimental stroke in mice even when
administered in a prophylactic setting. This is in line with
a previous investigation showing that GA does not reduce
stroke volumes or functional deficits on day 3 and day 7
after transient or permanent MCAO despite a downregu-
lation of pro-inflammatory cytokines [10]. In contrast,
Ibarra et al. [9] reported that GA exerts beneficial effects
on stroke outcome both histologically and clinically after
tMCAO in rats when applied 30 min after reperfusion.
However, in this study GA-induced neuroprotection be-
came manifest not before day 7. The exact reasons for
these discrepant findings are unclear at present but dif-
ferences in the stroke models (transient vs permanent) or
animal species (rat vs mice) used certainly play a role. In
addition, the dosing regimens including the time of
GA-application (prophylactic vs therapeutic) differed bet-
ween the two ancestor studies and ours.
GA has already been tested in other neurodegenerative
disease models apart from stroke and EAE but again
with divergent results [16]. While GA protected from
axonal and neuronal degeneration after optic nerve
crush [17,18] or in a mouse model of Alzheimer’s dis-
ease [19], the substance was ineffective in animal models
of amyotrophic lateral sclerosis [20,21]. However, even if
GA might mediate some neuroprotection in primarily
neurodegenerative diseases its application in ischemic
stroke appears less promising.
Several studies already exist that addressed the thera-
peutic potential of other immunomodulatory agents in
models of ischemic stroke. Treatment with FTY720,
which sequesters T lymphocytes within their lymphoid
organs [22] and which is also approved for the treatment
of multiple sclerosis, protects from ischemic neurodegen-
eration by reducing the interplay between thrombotic and
inflammatory processes (‘thrombo-inflammation’) in the
cerebral microvasculature [11]. However, other modes of
FTY720 action such as blood–brain barrier stabilization,
reduction of immune cell infiltration or direct neuropro-
tection might also play a role [23,24]. Similarly, blocking
of the very late antigen-4/vascular adhesion molecule-1
axis by injecting a monoclonal antibody against CD49d
(the murine equivalent of natalizumab) has been shown
to shield the brain against deleterious neuroinflamma-
tion after stroke in rodents [25,26] although an identical
approach was ineffective in our hands (unpublished
observations).
Our study has several limitations. First, we only focused
on the outcome at a very early stage after stroke (day 1).
Therefore, we cannot exclude neuroprotective effects of
GA that become operative only at more advanced stages
of infarct development [9]. Moreover, different GA dosingor application regimes could have produced different re-
sults. Finally, we refrained from conducting profound
mechanistic studies since we did not find an obvious
phenotype in GA-treated animals.
Taken together, our study failed to confirm a protective
effect of GA in acute ischemic stroke in mice. Neverthe-
less, the concept of immunomodulation in brain ischemia
is still tempting given the promising reports on other im-
munomodulatory agents. Further studies in relevant dis-
ease models are warranted.
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